

# Bruce Randazzo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2764992/publications.pdf>

Version: 2024-02-01

8  
papers

1,864  
citations

1162889  
8  
h-index

1588896  
8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

1345  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2317-2324.	1.1	17
2	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 936-945.	0.6	71
3	Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. <i>Lancet</i> , The, 2019, 394, 831-839.	6.3	250
4	Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1830-1834.e6.	0.3	22
5	Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions. <i>JAMA Dermatology</i> , 2018, 154, 676.	2.0	90
6	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 405-417.	0.6	673
7	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 418-431.	0.6	554
8	Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 594-603.	0.6	187